澳大利亚在primary HPV筛查背景下下一代九价人乳头瘤病毒疫苗的成本效果:比较建模分析
该比较建模分析用Policy1-Cervix与HPV-ADVISE两个动态模型,评估在澳大利亚男女均接种疫苗并转向每5年一次HPV初筛的背景下,九价HPV疫苗(HPV9)相对四价疫苗(HPV4)的成本效果。结果显示,HPV9要成为HPV4的成本效果替代方案,女孩每剂增量成本不应超过中位AUS$35·99(80%UI 28·47-41·18,Policy1-Cervix)或AUS$22·74(15·49-34·45,HPV-ADVISE),阈值为每质量调整生命年AUS$30 000。作者结论认为,按中位结果,每剂额外成本为AUS$23-36(US$18-28)时HPV9是HPV4的成本效果替代方案。
要点
- 与细胞学筛查相比,HPV筛查预计使终生宫颈癌诊断风险降低18%、死亡风险降低20%,即使在未接种队列中。
- 在基础情形假设下,与细胞学筛查相比,HPV4使未接种队列诊断进一步降低54%、死亡降低53%,HPV9使诊断和死亡均进一步降低11%。
- 作者认为,按中位结果,每剂额外成本AUS$23-36(US$18-28)时HPV9是HPV4的成本效果替代方案。
核心结论
- 按中位结果,若女孩每剂额外成本为AUS$23-36(US$18-28),HPV9将是HPV4的成本效果替代方案。
- 两种模型的方法与假设不同,导致估计结果存在一定差异。
研究设计与样本
- 采用Policy1-Cervix与HPV-ADVISE两个HPV传播、疫苗接种和宫颈筛查动态模型进行成本效果比较建模分析。
- 设定为终生疫苗保护、两剂接种,额外成本仅发生在女孩。
- 用两个模型对成本效果结果做概率敏感性分析,结果以模拟运行的中位数及第10至90百分位数(80%不确定性区间[UI])表示。
主要发现
- 与细胞学筛查相比,HPV筛查预计使终生宫颈癌诊断风险降低18%、死亡风险降低20%,即使在未接种队列中。
- 在基础情形假设下,与未接种队列的细胞学筛查相比,HPV4使诊断进一步降低54%、死亡进一步降低53%。
- 在基础情形假设下,与未接种队列的细胞学筛查相比,HPV9使诊断和死亡均进一步降低11%。
关键数值与推荐
- HPV9相对HPV4保持成本效果时,女孩每剂增量成本不应超过中位AUS$35·99(80%UI 28·47-41·18,Policy1-Cervix)。
- HPV9相对HPV4保持成本效果时,女孩每剂增量成本不应超过中位AUS$22·74(80%UI 15·49-34·45,HPV-ADVISE)。
- 上述阈值对应每质量调整生命年AUS$30 000的支付意愿阈值。
临床怎么用
- 作者认为,按中位结果,每剂额外成本AUS$23-36(US$18-28)时HPV9是HPV4的成本效果替代方案。
- 作者指出,这些结果在确定澳大利亚疫苗最优价格时具有重要意义。
局限性
- 两种模型的方法与假设不同,导致估计结果存在一定差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: First generation bivalent and quadrivalent human papillomavirus (HPV) vaccines have been introduced in most developed countries. A next generation nonavalent vaccine (HPV9) has become available, just as many countries are considering transitioning from cytology-based to HPV-based cervical screening. A key driver for the cost-effectiveness of HPV9 will be a reduction in screen-detected abnormalities and surveillance tests. We aimed to evaluate the cost-effectiveness of HPV9 in Australia, a country with HPV vaccination of both sexes that is transitioning to 5-yearly HPV-based screening. METHODS: We used Policy1-Cervix and HPV-ADVISE-two dynamic models of HPV transmission, vaccination, and cervical screening-to estimate the cost-effectiveness of HPV9 versus quadrivalent vaccine (HPV4), assuming lifelong vaccine protection, two vaccine doses, and that additional costs were incurred in girls only. Policy1-Cervix was used to estimate the lifetime risk of cervical cancer diagnosis and death. Probabilistic sensitivity analysis of the cost-effectiveness outcomes was done with both models, and results are presented as the median and 10th to 90th percentiles of simulation runs (referred to as 80% uncertainty intervals [UIs]). FINDINGS: Compared with cytology-based screening, HPV screening is predicted to reduce lifetime risk of cervical cancer diagnosis by 18% and of death by 20%, even in unvaccinated cohorts. Under base-case assumptions (lifelong protection, full efficacy at two doses), HPV4 will provide a further reduction in diagnosis of 54% and in death of 53% and HPV9 will provide a further reduction in both diagnosis and death of 11%, compared with cytology-based screening in unvaccinated cohorts. For HPV9 to remain a cost-effective alternative to HPV4, the incremental cost per dose in girls should not exceed a median of AUS$35·99 (80% UI 28·47-41·18) with Policy1-Cervix or AUS$22·74 (15·49-34·45) with HPV-ADVISE, at a willingness-to-pay threshold of AUS$30 000 per quality-adjusted life-year. INTERPRETATION: Differing methods and assumptions led to some differences in the estimates produced by the two models. However, on the basis of median results, HPV9 will be a cost-effective alternative to HPV4 if the additional cost per dose is AUS$23-36 (US$18-28). These results will be important when determining the optimum price of the vaccine in Australia. FUNDING: National Health and Medical Research Council, Australia.
引用
- Simms KT, Laprise JF, Smith MA, et al. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Lancet Public Health. 2016. PMID: 29253419. doi:10.1016/S2468-2667(16)30019-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。